Wave Life Sciences (WVE) is back in focus after the company started the Phase 2a multidose part of its INLIGHT trial for obesity drug candidate WVE-007, following encouraging Phase 1 single dose data.

Against the backdrop of the INLIGHT trial progress, Wave Life Sciences’ recent share price performance has been weak, with the stock down 6.71% over 30 days and 19.78% over 90 days, while the 3 year total shareholder return of 53.28% points to a very different longer term experience.

If obesity drug development has caught your attention, it could be a good moment to broaden your watchlist with other healthcare related AI opportunities through our 39 healthcare AI stocks.

With Wave Life Sciences shares down sharply year to date yet trading at a steep discount to the average analyst price target, the key question is whether sentiment is too pessimistic or whether the market is already factoring in potential future growth.

Most Popular Narrative: 73.7% Undervalued

Based on the most followed narrative, Wave Life Sciences’ fair value of $22.19 sits well above the last close at $5.84. This frames a large valuation gap that hinges on how its RNA platform and obesity program play out.

The expansion and clinical validation of Wave's proprietary RNA editing and siRNA platforms, including the emergence of new wholly-owned pipeline candidates for both rare and prevalent diseases, position the company to benefit from growing market adoption of RNA-based and precision therapies, underpinning longer-term top-line growth and partnership revenue potential.

Analysts are effectively pricing in a step change for Wave Life Sciences, built on faster revenue growth, improving margins, and a premium multiple that assumes its key programs hit important clinical and regulatory milestones.

Result: Fair Value of $22.19 (UNDERVALUED)

However, the Wave Life Sciences narrative still faces pressure from widening losses of $183.6 million and heavy reliance on a small group of high risk pipeline programs.

Another View on Wave Life Sciences’ Valuation

The earlier narrative leans on long term revenue growth and earnings assumptions to argue Wave Life Sciences looks undervalued at a fair value of $22.19 versus the $5.84 share price. On simple P/S though, the stock trades at 15.6x, far above the US pharmaceuticals industry at 6x, peers at 1.2x, and an estimated fair ratio of 1.3x. This points to considerable valuation risk if expectations reset.

For a closer look at how this gap between today’s pricing and the fair ratio stacks up, and what the numbers imply for future re rating risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Wave Life Sciences split between concern about risks and optimism around potential rewards, it helps to test the numbers yourself and move quickly while the data is fresh, starting with the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond Wave Life Sciences?

If Wave Life Sciences has sharpened your focus on opportunities, do not stop here. Use focused stock lists to uncover other ideas that match your investing style.

• Target potential bargains that pair quality with attractive pricing by scanning the 41 high quality undervalued stocks and see which stocks stand out right now.
• Strengthen your watchlist with companies that put balance sheet resilience first by reviewing the solid balance sheet and fundamentals stocks screener (47 results) before the crowd catches on.
• Get ahead of the pack by checking the screener containing 19 high quality undiscovered gems and spot lesser known stocks with fundamentals that might deserve a closer look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.